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The Role of Oncogenes in Chemical
Carcinogenesis
by S. Jill Stowers,* Robert R. Maronpot,t Steven H.
Reynolds,* and Marshall W. Anderson*
Proto-oncogenes are cellular genes that are expressed during normal growth and developmental pro-
cesses. Altered versions of normal proto-oncogenes have been implicated in the development of human
neoplasia. In this report, we show the detection ofactivated proto-oncogenes in various spontaneous and
chemically induced rodent tumors. The majority of activated proto-oncogenes found in these tumors are
members of the ras gene family and have been activated by a point mutation. Characterization of the
activating mutation may be useful in determining whether this proto-oncogene was activated by direct
interaction ofthe chemical with the DNA. Comparison ofactivating lesions in spontaneous versus chem-
ically induced tumors should be helpful in determining whether the chemical acts via a genotoxic or a
nongenotoxic mechanism. All of this information may be helpful in the assessment of potential carcin-
ogenic hazards of human exposure to chemicals.
Introduction
Recent evidence suggests that neoplastic develop-
ment, at least in part, is the result of the abnormal
activation of a small set ofcellular genes. These genes,
termed proto-oncogenes, were originally discovered as
the transduced genes of acute transforming retrovi-
ruses (1-3). Subsequent studies have established that
these proto-oncogenes can also be activated as onco-
genes by mechanisms independent of retroviruses (4).
Mechanisms for the conversion of proto-oncogenes to
activated oncogenes include point mutations, gene am-
plification, chromosomalrearrangements, and promoter
insertion (Fig. 1). The activation ofproto-oncogenes by
geneticalterationsresults inalteredlevels ofexpression
of the normal protein product, or in normal or altered
levels of expression of an abnormal protein.
Proto-oncogenes are expressed during regulated
growth such as embryogenesis, regeneration of dam-
aged liver, and stimulation of cell mitosis by growth
factors. Proto-oncogenes are highly conserved. They
are detected in species as divergent as yeast, Droso-
phila, and humans. Proto-oncogenes include genes that
encode forgrowth factors (sis), growth factor receptors
(neu, erbB, fms), regulatory proteins in signal trans-
duction (ras family), nuclear regulatory proteins (myc,
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myb, fos), and tyrosine kinases (scr, abl, ras). Thus,
the encoded proteins appear to play a crucial role in
normal cellular growth and/or differentiation.
The activation ofproto-oncogenes in spontaneous and
chemicallyinduced tumorshasbeenextensivelystudied
duringthe past severalyears. Although oncogenes such
as ras and myc can complement each other in the ma-
lignant transformation ofa cell in vitro (2), the number
of proto-oncogenes that must be activated in the mul-
tistep process of carcinogenesis is unclear at present.
Also, new evidence from several laboratories suggests
that in addition to the activation ofpositive factors (on-
cogenes), the loss ofnegative regulatory functions (tu-
mor suppressor genes) may also be a necessary but
distinct step in neoplastic development (5). This paper
will discuss the detection of activated oncogenes in ro-
dent tumors and the implication of oncogenes in risk
analysis of carcinogen-induced rodent tumor data.
Detection of Activated Oncogenes
in Tumors
Detection of activated oncogenes in neoplasia can be
achieved by using several different techniques depend-
ing on how the particular oncogene might be activated.
Abnormal expression of oncogenes in tumors due to
amplification of the gene may be detected by dot blot
or Southern blot analysis. Increased expression due to
deregulation of the gene may be detected by dot blot
as well as Northern blot analysis. Chromosomal trans-
locations may be detected by cytogenetic analysis. Ex-STOWERS ETAL.
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FIGURE 1. Mechanisms of proto-oncogene activation.
amples of abnormal expression of oncogenes detected
inhumantumorsandtumorcelllinesareshowninTable
1.
A number of oncogenes present in human tumors as
well as animal tumors have been detected by the NIH/
3T3 transfection assay. The NIH/3T3 transfection tech-
nique involves the ability ofthe NIH/3T3 mouse fibro-
blast to accept and express genes from donor tumor
DNA, resulting in the formation of transformed cells.
Only a few years ago, Shih et al. (6) were the first to
show that DNA from carcinogen-transformed cell lines
could causetransformation ofNIH/3T3cellsaftertrans-
fection. This transformation was characterized by a
change in the morphology ofthe NIH/3T3 cells and by
anchorage-independentgrowth. Otherinvestigators us-
ingthistechnique werethenabletoshowthatdominant
transforning genes or oncogenes were present in hu-
man tumors and in carcinogen-induced animal tumors.
An extension of the NIH/3T3 transfection assay that
affords greater sensitivity is the nude mouse tumori-
genicity assay (7). This involves cotransfection ofNIH/
3T3 cells with tumor DNA and a selectable marker
Table 1. Abnormal expression of oncogenes in human tumors
and tumor cell lines.
Mechanism Tumor type Oncogene Reference
Amplification Breast tumor neu (24)
Amplification Squamous cell c-erbB (25)
carcinoma
Amplification Small cell lung c-myc (26)
carcinoma
Amplification Small cell lung L-myc (27)
carcinoma
Amplification Neuroblastoma N-myc (28)
Amplification Acute myelogenous c-myb (29)
leukemia
Translocation Chronic myelogenous c-abl (80)
leukemia
Translocation Burkitt's lymphoma c-myc (31)
gene. The selected cells are then injected SC into the
immunocompromised mice. The tumors that develop
from the nude mice are then analyzed using the tech-
niques described earlier to characterize the activated
oncogenes.
The majority ofactivated genes in human tumors de-
tected bythe NIH/3T3 assay havebeenmembers ofthe
ras gene family: the H-ras, the K-ras, and the N-ras.
Earlystudiesusingthe NIH/3T3 assay showed only ras
geneactivationin alowpercentageofthehumantumors
(approximately 10%). Later studies have shown that
other oncogenes can also be detected in the human tu-
mors by this assay, including the Ica (8), hst (9), and
the trk (10) oncogenes. In addition, the percentage of
certain tumor types that test positive for activated ras
oncogenes are higher than 10%. For example, Verlaan-
deVries et al. (11) detected activated ras genes in the
27% of acute myeloid leukemia examined. Ananthas-
wamy et al. (12) detected Ha-ras genes in four of six
human squamous cell carcinomas examined. The addi-
tion of the tumorigenicity parameter to the assay sys-
tem appears to improve the efficiency in detection of
activated oncogenes in human tumors.
A variety of animal tumor model systems have also
been examined for activated genes using the NIH/3T3
assay. These include spontaneous tumors in rats and
mice, tumors that arise after single or multiple doses
of carcinogen, and tumors that arise after long-tern
exposure to a carcinogen. Examples of the activated
genes in the different tumor model systems are shown
in Table 2. Like the human tumors, the majority of
activated oncogenes detected in the animal tumors are
members ofthe ras gene family. Other oncogenes have
also been detected in animal tumors usingthe NIH/3T3
assay (Table 3). One example is the activated neu on-
cogene found in nervous tissue tumors induced in rats
by transplacental exposure to N-methyl-N-nitrosourea
(MNU) orN-ethyl-N-nitrosourea (ENU). The c-rafon-
Promoter/Enhancer LTR/c-onc P LTR/Common Insertion Domain
Chronic, Non-
Transforming
Leukemia Virus
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Table 2. Activated oncogenes in rodent tumor models.
Number positive/
Number tested
17/27
1/37
61/71
6/29
Oncogene
H-ras (15)a, raf(1), unknown (1)
H-ras (1)
H-ras (61)
H-ras (6)
Single dose, neonatal
HO-AAFb
HO-DHE
vC
DEN
Multiple doses
DMN-OME
Aflatoxin B,
Mouse liver
Mouse liver
Mouse liver
Mouse liver
10/10
11/11
10/10
14/33
Rat renal
Rat liver
10/35
10/11
H-ras (10)
H-ras (10), K-ras (1)
H-ras (10)
H-ras (14)
K-ras
K-ras (2), unknown (9)
Continuous dose
TNM
Furan
Furfural
Benzidine-derived dyes
DEN
Rat and mouse liver
Mouse liver
Mouse liver
Ratd
Rat liver
18/19, 10/10
13/29
13/16
34/58
1/12
K-ras (18), K-ras (10)
H-ras (10), raf(1), K-ras (2)
H-ras (9), K-ras (1), unknown (3)
H-ras (31), N-ras (3)
Unknown
Initiation-promotion
DEN-Farber protocol
DEN + PB
DEN + EE2
DMBA + TPA
Rat liver
Rat liver
Rat liver
Mouse skin
0/20
0/10
2/19
33/37
non-ras (2)
H-ras
(36)
c
f
(37)
Transplacental dose
ENU Rat neuroblastomas 3/3 neu (3) (38)
MNU Rat schwannomas 10/13 neu (10) (16)
aNumbers in parentheses are the number of positive samples with that oncogene.
'Abbreviations: HO-AAF, N-hydroxy-2-acetylaminofluorene; HO-DHE, 1'-hydroxy-2',3'-dehydroestragole; VC, vinyl carbamate; DEN, N-
nitrosodiethylamine; DMN-OMe, methyl(methoxymethyl)nitrosamine; PB, phenobarbital; EE2, ethinyl estradiol. For other abbreviations, see
text.
'Stowers et al., unpublished data.
dBenzidine-derived dye-induced rattumorsinclude preputialgland tumors, squamous cell carcinomas, basalcelltumors, clitoralglandtumors,
and mammary tumors.
'Reynolds and Anderson, unpublished data.
fGoodrow et al., unpublished data.
cogene has also been detected in mouse liver tumors.
The detection ofunusual mutations in the ras genes, as
well as the identification of new classes of oncogenes in
animal tumors, should be enhanced by the addition of
the nude mouse tumorigenicity assay.
Activation of Oncogenes by
Carcinogens
Studies in animal tumor model systems suggest that
the chemicals or radiation may play a role in the acti-
vation of oncogenes by point mutation. Point mutations
resultingintheactivation ofras proto-oncogenes in sev-
eral chemically induced rodent tumors have been con-
sistent with the known alkylation patterns of the car-
cinogens (13). For example, the mutation at the 12th
codon of the H-ras gene detected in rat mammary tu-
mors induced by methylnitrosourea (14) is consistent
with the formation ofthe o6 methylguanine adduct. The
activating mutation in the 61st codon ofthe H-ras gene
found in 7,12-dimethylbenz[a]anthracene (DMBA)-in-
duced mammary tumors and skin tumors is consistent
with DMBA binding to adenosine residues (15). The
point mutation that activates the neu proto-oncogene
in peripheral nervous system tumors in rats induced by
ENU or MNU probably results from the binding of
these potent genotoxic chemicals to DNA (16). "Hot
spots" for activatingmutations in these oncogenes have
been observed (17). For example, the GGA-* GAA mu-
tation observed in the 12th codon of ras oncogenes de-
tected in MNU-induced mammary carcinomas (14) is
always atthe second guanine ofthis codon, eventhough
asimilarmutationatthefirstguaninecouldalsoproduce
an activated ras oncogene. Ifthe sequence ofspecificity
for the binding of carcinogens to DNA corresponds to
a known biological hot spot in an oncogene, then this
chemical can be a very potent carcinogen.
Several studies have shown that oncogene activation
maynotbethe directresultofchemicalinteractionwith
DNA. Activated oncogenes have been detected in a
number ofdifferent types oftumors in the mouse. This
Model
Spontaneous
Single dose
NMU
DMBA
Tumor
Mouse liver
Rat
Rat mammary
Rat mammary
Reference
(18,32)
(18)
(14)
(15)
(33)
(33)
(33)
c
(34)
(35)
(19)
(23)
(23)
e
c
83STOWERS ET AL.
Table 3. Non-ras oncogenes detected in human and rodent
tumors.
Table 4. Detection of activated K-ras oncogene in
tetranitromethane-induced lung tumors in mice and rats.
Tumor Treatment Oncogene Reference
Neuroblastomas (R)a ENU neu (38)
Schwannomas (R) MNU neu (16)
Stomach carcinomas hst (9)
(H)
Colon carcinomas (H) trk (10)
Hepatocellular Untreated raf (23)
carcinomas (M)
Hepatocellular lca (8)
carcinoma (H)
Hepatocellular AFB,b (35)
carcinomas (R)
Hepatocellular Untreated ? (23)
carcinoma (M)
Hepatocellular Furfural ? (23)
carcinomas (M)
Pulmonary Untreated ? c
adenocarcinoma (M)
Nasal squamous MMS ? (13)
carcinomas (R)
Skin carcinoma (M) DMBA ? (17)
Skin carcinoma (M) DB[c,h]ACR ? (17)
aLetters in parentheses indicate species in which tumors occur. R,
rat; M, mouse; H, human.
bAbbreviations: AFBj, aflatoxin B1; MMS, methylmethanesulfo-
nate; DB[c,h]ACR, dibenz[c,h]acridine
CJU. Candrian and M.W. Anderson, unpublished data.
implies that activation of oncogenes in long-term car-
cinogenic studies in the mouse may or may not be the
result of direct interaction of the chemical with DNA
(U. Candrian, unpublished data; 18). It is possible in
some instances that the chemical did activate the on-
cogenedirectly andis consistent withthe chemicalbind-
ing to the DNA. In other instances, the chemical may
have increased the background tumor incidence by a
mechanism such as cytotoxicity or receptor-mediated
promotion. Ifthe pattern ofactivated oncogenes in the
chemically induced tumors is different from that in the
spontaneously occurring tumors, then the chemical
probably caused the mutations, at least in some ofthe
tumors. One example in which the chemical's role in
oncogene activation is not known is the activated K-ras
oncogenedetectedintetranitromethane (TNM)-induced
rat and mice lung tumors. TNM is a mutagen and an
irritant. However, the interactions between TNM and
DNA are not known. In a recent long-term carcinogen-
esis study conducted by the NTP, chronic exposure to
TNM resulted in a high incidence of primary lung tu-
mors in Fischer 344 rats and B6C3F1 mice (19). K-ras
oncogeneswithaGGT-)GATmutationinthe 12thcodon
were observed in 18 of 19 rat lung tumors and 10 of 10
mouse lung tumors (Table 4). The activation of the K-
ras oncogene in these TNM-induced lung tumors may
be the result of one or more actions of the chemical: a
direct consequence ofTNM-induced DNA damage; the
tumors may be spontaneously occurring; enhancement
ofspontaneously occurring K-ras by TNM-induced cell
replication; orcombination ofdirectTNM-induced DNA
damage and enhancement of spontaneous occurrence.
It is a distinct possibility that these activated K-ras
DNA source
Transforming K-ras gene with
GGT-*GAT mutation in 12th
codon,a
number positive/number tested
Rat adenocarcinoma 12/12 (100%)
Rat squamous cell carcinoma 3/4 (75%)
Rat adenosquamous carcinoma 3/3 (100%)
Mouse adenocarcinoma 8/8 (100%)
Mouse adenoma 2/2 (100%)
aThe presence of transforming genes was detected by NIH/3T3
transfection and/or oligonucleotide hybridization, and the frequency
oftransforming genes isrepresentedby the numbers inparentheses.
oncogenes with GC--AT transitions in the second base
of the 12th codon are spontaneous, since an activated
K-ras with the same mutation was observed in a spon-
taneously occurring pulmonary adenocarcinoma in the
B6C3F1 mouse (U.Candrian, unpublished data). Even
though spontaneous lung tumors in the Fischer 344 rat
were not observed in this study, it is still possible that
the irritant property of TNM could have promoted the
cells, which activated the K-ras or enhanced the spon-
taneously occurring K-ras. The reproducible detection
of the K-ras in lung tumors of mice and rats suggests
that TNM could have directly induced the mutation. In
support of this conclusion, mutagenicity studies have
shownthatTNMcausesmutantbacterialstrainstorev-
ert to the wild type by the same GC-*AT transition.
Studies on the possible interactions ofTNM with DNA
are required to precisely determine the origin of the
activated K-ras oncogenes in these TNM-induced lung
tumors.
Although gene amplification and chromosomal trans-
location have been observed in several types ofhuman
tumors, these activating mechanisms have not been ex-
tensively observed or studied in spontaneous or chem-
ically induced rodent tumors. Sawey et al. (20) did ob-
serve c-myc gene amplification and restriction poly-
morphisms in addition to activated K-ras genes in rat
skin tumors induced by ionizing radiation. Quintanilla
et al. (21) suggested that amplification of the mutated
H-ras genemaybeinvolved intheprogressionofmouse
skin papillomas to carcinomas. Further studies are re-
quired to determine the possible role of chemicals and
radiation in the activation of proto-oncogenes by gene
amplification, chromosomal translocation, and other
mechanisms that can alter gene expression.
Carcinogen-inducedrodenttumormodelsmaybeuse-
ful in determiningthe temporal activation ofoncogenes
intumordevelopment. Evidenceinseveralanimalstud-
ies suggests that activation of the ras proto-oncogene
is an early event. The activated ras gene has been de-
tected in many benign tumors, including mouse skin
papillomas, mouse lung and liver adenomas, and basal
cell and clitoral gland tumors of the rat. This implies
that the activated ras was present in the cell that clon-
ally expanded to these benign tumors. In addition, it
was recently shown that mouse epidermal cells injected
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invivo with the viral Ha-ras gene canbepromotedwith
12-0-tetradecanoyl-phorbol-13-acetate (TPA) to papil-
lomas (22). Thus, activation of the ras proto-oncogene
may be the initiation event in some model systems.
Moreover, dormantinitiated cellswiththe activatedras
gene can survive surrounded by normal cells until stim-
ulated to proliferate by some endogenous or exogenous
agent.
Implications for Risk Analysis
The number of proto-oncogenes that must be acti-
vated in order to convert a normal cell into one that is
tumorigenic is unknown at present. However, there is
increasing evidence that the transformation ofanormal
cell into a tumorigenic cell involves the activation and
concerted expression ofseveralproto-oncogenes as well
as, perhaps, the inactivation ofsuppressor genes. Con-
tinued research on mechanisms of oncogene activation
in animal and in vitro models may provide new insights
into several long-standing problems in chemical carcin-
ogenesis and risk analysis of carcinogenesis data.
Oncogene analysis on tumors from long-term carcin-
ogenesis studies that are employed to help identify po-
tentialhumancarcinogenscanbeusefulinseveralways.
The analysis can help identify chemicals that can acti-
vate proto-oncogenes in vivo to cancer-causing genes.
Model systems very susceptible to chemically induced
tumors, suchasthe B6C3F1 mouselivertumors, appear
to be suited for this purpose (23). The classification of
chemicals as initiators, promoters, complete carcino-
gens, etc., maybecome clearer as webetterunderstand
the sequential requirements for activation ofoncogenes
in the various animal model and cell culture systems.
In particular, comparison of patterns of oncogene ac-
tivation in spontaneously occurring and chemical-in-
duced tumors should assist in determining mode(s) of
action ofa carcinogen. Low-dose and species-to-species
extrapolationofriskfromcarcinogenicdatamaybecome
more reliable from examination of oncogene activation
and expression in animal model systems for carcino-
genesis. These and similar approaches to explore the
mechanismsbywhichchemicalsinducetumorsinanimal
model systems may remove some ofthe uncertainty in
risk analysis ofrodent carcinogenic data.
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